TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Effectiveness of treatment for granuloma umbilica
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effect on patient's target symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of anaesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Change From Baseline in SALT Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: intrapulmonary lung deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of children with protective antiHBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Binge drinking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of orally administered tafamidis
Endpoint domain: Adverse events/effects
Primary endpoint: duration of time living at home
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Cardiac Necrosis Biomarkers (CKMB, Troponin I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflammation Marker (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to dietary sodium and medication taking behavior
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Agility and speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper-body strength and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of survivors in patients with AKI diagnosis during ICU
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of NIRS measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal adaptation of laminates veneers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response to Thrombin Generation Assay (TGA), D-Dimer, F1.2 prothrombin fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proximal Adenoma detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CSF levels of lymphocyte subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: markers of neuronal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Verbal scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-efficacy: Healthful Eating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Goal Commitment: Healthful Eating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy: Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Goal Commitment - Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in average monthly migraine-days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects who liked using the RebiSmart device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of TCD-717
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects achieving hemostasis at the Target Bleeding Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Midazolam time to maximal plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midazolam maximal plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of target tibial slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Achievement of target tibial varus/valgus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decreased insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ongoing pregnancy rate beyond 20 weeks
Endpoint domain: Mortality/survival
Primary endpoint: diaphragmatic ultrasound thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: diaphragmatic ultrasound thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: diaphragmatic ultrasound excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Pain (VAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areal bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of severe clinical toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: absence of procedure-related neurological deficits
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hamilton Anxiety Rating Scale (HAMD) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in GAD-7 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of propranolol administration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of New Clinically Diagnosed Actinic Keratoses or Squamous Cell Carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PCA morphine or pain rescuer consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain score (visual analogue scale 0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-2, interleukin-4, interleukin-10, interleukin-17, RANTES, GDF-15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stem cell growth factor β
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipsin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropeptide Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular Endothelial Growth Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Alexithymia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentages of Subjects With hSBA Titers ≥ 1:4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bleeding rate of the puncture site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to Having no Pain Following Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Weight From Baseline to 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamate blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urine drug screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of oral mucositis (Over Grade 1)
Endpoint domain: Adverse events/effects
Primary endpoint: neurodevelopmental function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Joint perception task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycosylated Hemoglobin (HbA1c) Under 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients undergoing revascularization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hemodynamic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerance of the endotracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with liver venous thrombosis recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Subclinical lung alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: UACR percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection of endoleak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Illicit Opioid Use
Endpoint domain: Adverse events/effects
Primary endpoint: Physiologic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in Lung Clearance Index (LCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetics of 14C-labeled Anlotinib: Area under the plasma concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Reported Unanticipated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients completing CBT-I program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Inhaler technique errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Total Length of Operative Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Opiate pain medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of orthodontic canine movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to get COVID-19 vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of glenohumeral rotation degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or Higher Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Fetal Deaths or Stillbirths
Endpoint domain: Mortality/survival
Primary endpoint: Number of Congenital Birth Anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Improved physician counseling
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Presence or absence of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best overall response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Cystoid Macular Edema (CME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Time to survival
Endpoint domain: Mortality/survival
Primary endpoint: Concentration of HDM allergen to induce bronchial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bladder Intact Event-free Survival (BI-EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of babies with birth weight below 10th centile for gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Stillbirth or fetal death or miscarriages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: muscle disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: residual astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total corneal astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of bronchiolitis obliterans syndrome (BOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Visual Acuity Mean Score in the Amblyopic Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Visual Acuity in the Amblyopic Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-Body Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Migraine relief at 2 hours post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative migraine pain relief at 2 hours post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent responders resulted in significant pain relief at 2 hours post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement of rescue injection
Endpoint domain: Adverse events/effects
Primary endpoint: Total cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Survival at 30 Months
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects Achieving Oral Treprostinil Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colony forming units (CFU) Pre-Prep 48h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Colony forming units (CFU) Pre-Prep 72h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Colony forming units (CFU) Post-Prep 48h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Colony forming units (CFU) Post-Prep 72h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUC(0-∞) of total drug-related material in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of GW642444 following oral dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eye Contact/Gaze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC0-6 at Day 85
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 AUC0-4 at Day 85
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 AUC4-6 at Day 85
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Steroid Sparing Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Study Participants With Treatment-related Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement of test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of improvement in overactive bladder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain acceptance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: stricture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time when stricture occurs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Melanocyte number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melanocyte phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melanogenesis characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive skin test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Observed Plasma Concentration of Penciclovir (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Plasma Concentration of Penciclovir (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Penciclovir Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Patient Perception of Bladder Condition Score (PPBC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Technical Success at Time of Initial Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Oxidation index of the Polyethylene Inlay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toll like receptor 2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate and Extend of absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Cognition Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline SPADI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of lymphatic vessels visualized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to disease progression or death
Endpoint domain: Mortality/survival
Primary endpoint: Smoking treatment outcomes (reductions or abstinence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of pancreatic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: recovery of bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants in Care at Six Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in percentage of time in glucose target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quantified Itch Survey
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Quantified Sleep Survey
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Quantified Quality of Life Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall safety of pacritinib in patients with treatment refractory solid tumors
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Platelet Count ≤600x10^9/L After 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fMRI data comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects That Would Have This Procedure Again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of Swallowing the Sponge Device
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mucosal Irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under The Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Maximum Observed Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG (12-lead ECG) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vital sign measurements (blood pressure & heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of specific HCMV-/VZV-IgG-antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biodistribution of copper Cu 64 DOTA-B-Fab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosimetry of copper Cu 64 DOTA-B-Fab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy parameters (sensitivity, specificity, NPV, PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pathological diagnosis of ovarian lumps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants with High Grade TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Total body BMD (total body less head)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: Lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: Volumetric BMD of distal radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: Feasibility of using the Hilotherm mask
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of sensory block of the upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of motor blockade of the upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Readiness for surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement of speaking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Oral Feeding Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients alive at 6 months
Endpoint domain: Mortality/survival